MAST2 and glioblastoma: Following co-treatment with TRAIL and two different proteasome inhibitors (a promising combination for future glioblastoma therapy [65]), the apoptotic profile of MAST2 shRNA U87 cells was assessed and we observed a significant increase in apoptosis sensitivity in the absence of MAST2 (Fig. 4D), thereby confirming the anti-apoptotic potential of this kinase.